10-Q quarterly report · filed Nov 5, 2026

Steris (STE) Q3 2026 10-Q Quarterly Report

Short answer

Steris (STE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (up 8.8% year over year) with net income of $214M.

Q3 2026 key financials · XBRL

Revenue
$1.6B
+8.8% YoY · +6.4% QoQ
Net income
$214M
+11.4% YoY · +6.8% QoQ
Operating margin
18.5%
Gross margin
44.7%

Source: XBRL data from the Steris (STE) Q3 2026 10-Q on SEC EDGAR. USD.

Steris Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q2 revenue $1,588.6M, up 8.8% YoY from $1,460.3M
  • Gross margin 44.7% vs 44.2% YoY; operating income $294.3M vs $265.8M
  • Best segment Life Sciences: revenue $170.6M, up 17.7%; margin 44.4% vs 41.3%
  • Healthcare weakest margin trend: 24.0% vs 25.1%, despite revenue growth of 8.6% to $1,122.4M
  • Six-month operating cash flow $656.1M vs $707.8M; free cash flow $492.5M vs $527.7M, with $200.0M share repurchases

Risk Factors

  • New transaction risk: Xodus Medical Acquisition could fail to close, with termination permitted after July 12, 2027
  • Regulatory risk: Hart-Scott-Rodino approval and other antitrust clearances could require divestitures or remedies
  • Operational risk: Acquisition uncertainty could cause employee departures and customer, supplier, or partner disruptions
  • Financial risk: Approximately $2.0 billion additional debt expected, versus $1.9 billion outstanding at September 30, 2026
  • Financing risk: Bridge facility may carry higher costs and shorter maturities if permanent financing terms prove unacceptable

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Steris quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.